Profound Medical Corp.PROFNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-4x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -99.92% |
| Q3 2025 | -12.14% |
| Q2 2025 | 26.83% |
| Q1 2025 | -28.62% |
| Q4 2024 | 19.90% |
| Q3 2024 | 33.62% |
| Q2 2024 | 6.57% |
| Q1 2024 | -25.82% |
| Q4 2023 | 55.74% |
| Q3 2023 | 8.24% |
| Q2 2023 | -18.10% |
| Q1 2023 | -18.61% |
| Q4 2022 | -27.59% |
| Q3 2022 | 78.77% |
| Q2 2022 | -8.03% |
| Q1 2022 | -41.96% |
| Q4 2021 | 33.38% |
| Q3 2021 | 51.49% |
| Q2 2021 | -17.82% |
| Q1 2021 | -7.35% |
| Q4 2020 | 24.85% |
| Q3 2020 | 107.21% |
| Q2 2020 | -18.47% |
| Q1 2020 | -16.45% |
| Q4 2019 | -2.33% |
| Q3 2019 | 6.58% |
| Q2 2019 | 21.02% |
| Q1 2019 | 12.87% |
| Q4 2018 | -10.93% |
| Q3 2018 | 11.74% |
| Q2 2018 | -8.40% |
| Q1 2018 | 0.97% |
| Q4 2017 | -14.87% |
| Q3 2017 | 21.95% |
| Q2 2017 | 31.66% |
| Q1 2017 | -26.93% |
| Q4 2016 | 1.38% |
| Q3 2016 | 9.72% |
| Q2 2016 | -8.92% |
| Q1 2016 | 86.74% |